Condition: Hypoxic-Ischemic Encephalopathy · Neonatal Asphyxia · Neonatal Encephalopathy · Sponsor: Pharmazz, Inc.
Sovateltide (PMZ-1620; IRL-1620) is targeted to be used as a "Treatment for hypoxic-ischemic encephalopathy in neonates," which is a life-threatening condition. Sovateltide augments neuronal progenitor cell differentiation and better mitochondrial morphology and biogenesis to activate a regenerative response in the central nervous system. The only treatment for HIE is therapeutic hypothermia with limited success, and studies indicate that sovateltide may be beneficial in these patients.
This description comes directly from the study's public registry record.
Manish S Lavhale · +91 9873847397 · manish.lavhale@pharmazz.com
Always discuss trial participation with your own doctor first.
| Father Muller Medical College Hospital | Mangalore, Karnataka, India | Recruiting |
| Christian Medical College and Hospital | Ludhiana, Punjab, India | Recruiting |
| Niloufer Hospital | Hyderabad, Telangana, India | Not Yet Recruiting |
| GSVM Medical College | Kanpur, Uttar Pradesh, India | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05514340